---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104028"
form_type: "8-K"
ticker: "ARTV"
cik: "0001817241"
company_name: "Artiva Biotherapeutics, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:49:15.504521+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Artiva reports Q2 net loss $21.3M; cash runway into Q2 2027; autoimmune trial progress

## Summary
- Net loss of $21.3M for Q2 2025 vs $17.8M in Q2 2024; R&D expenses $17.9M (up from $12.3M).
- Cash, cash equivalents, and investments $142.4M as of June 30, 2025; funding into Q2 2027.
- First patient treated in global Phase 2a basket trial of AlloNK + rituximab in refractory RA, Sjögren's, myositis, and scleroderma.
- Over a dozen patients treated across autoimmune trials; initial safety/translational data by year-end 2025.
- Lead indication for AlloNK to be disclosed by year-end 2025; initial clinical response data in 1H2026.

## SEC filing metadata
- accession: 0000950170-25-104028
- form_type: 8-K
- ticker: ARTV
- cik: 0001817241
- company_name: Artiva Biotherapeutics, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817241/000095017025104028/0000950170-25-104028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817241/000095017025104028/artv-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104028
- JSON: https://secwatch.observer/filing/0000950170-25-104028.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.